Gilead Sciences Inc (NASDAQ:GILD), a leading biopharmaceutical company specializing in antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, stock rose 8.83% (As on August 8, 11:19:53 AM UTC-4, Source: Google Finance) after the company lifted its full-year financial guidance, thanks in part to steady demand for its HIV treatments. As of June 30, 2025, Gilead had $7.1 billion of cash, cash equivalents and marketable debt securities compared to $10.0 billion as of December 31, 2024. During the second quarter 2025, Gilead generated $827 million in operating cash flow, net of a final $1.3 billion transition tax payment associated with the Tax Cuts and Jobs Act of 2017.

Moreover, HIV product sales increased 7% to $5.1 billion in the second quarter 2025 compared to the same period in 2024, primarily driven by increased demand and higher average realized price. The Liver Disease portfolio sales decreased 4% to $795 million in the second quarter 2025 compared to the same period in 2024. This was primarily driven by lower HCV sales, partially offset by increased demand for Livdelzi, Hepcludex® (bulevirtide) and chronic hepatitis B virus (“HBV”) products. Veklury sales decreased 44% to $121 million in the second quarter 2025 compared to the same period in 2024, primarily driven by lower rates of COVID-19-related hospitalizations. Cell Therapy product sales decreased 7% to $485 million in the second quarter 2025 compared to the same period in 2024, reflecting ongoing competitive headwinds. Trodelvy sales increased 14% to $364 million in the second quarter 2025 compared to the same period in 2024.

GILD in the second quarter of FY25 has reported the adjusted earnings per share of $2.01, beating the analysts’ estimates for the adjusted earnings per share of $1.96. The company had reported the adjusted revenue growth of 2 percent to $7.1 billion in the second quarter of FY25, beating the analysts’ estimates for revenue of $6.97 billion. This is driven by higher HIV, Livdelzi (seladelpar) and Trodelvy (sacituzumab govitecan-hziy) sales, partially offset by lower chronic hepatitis C virus (“HCV”) and Veklury (remdesivir) sales. Total second quarter 2025 product sales excluding Veklury increased 4% to $6.9 billion compared to the same period in 2024.

Gilead also raised its full-year forecast, expecting 2025 adjusted income per share of $7.95 to $8.25. Its previous estimates were for $7.70 to $8.10. Annual product sales are now expected to be between $28.3 billion and $28.7 billion, versus a previous range of $28.2 billion to $28.6 billion.